Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial readout, as global demand for the technology increases. The company ...

The US Food and Drug Administration (FDA) has approved Edwards Lifesciences' SAPIEN 3 transcatheter aortic valve replacement (TAVR) platform for the treatment of patients with asymptomatic severe ...

SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the ...

Edwards Lifesciences Corp.’s posted fourth quarter results slightly ahead of expectations, but indicated that the first quarter of 2025 might not be as bright. The company expects growth for both its ...

Edwards Lifesciences has persuaded CMS to publish an updated tracking sheet for TAVR national coverage analysis. The move is causing CMS to reconsider its previous stance on covering transcatheter ...

SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...